The Pharmaceutical Research Manufacturers of America releases its voluntary code of conduct for the $4 billion direct-to-consumer advertising industry this afternoon, calling for a better presentation
of risk information and Food and Drug Administration pre-approval of all advertising, but falling well short of a mandate on the most serious issues.
Read the whole story at Adage.com, August 2, 2005 »